Duncan Williams Asset Management LLC Has $256,000 Stock Position in Eli Lilly and Company $LLY

Duncan Williams Asset Management LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 29.6% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 328 shares of the company’s stock after purchasing an additional 75 shares during the period. Duncan Williams Asset Management LLC’s holdings in Eli Lilly and Company were worth $256,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. WestEnd Advisors LLC lifted its stake in Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after acquiring an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC bought a new stake in shares of Eli Lilly and Company in the 1st quarter valued at about $27,000. Citizens National Bank Trust Department lifted its stake in Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock valued at $35,000 after purchasing an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. bought a new position in Eli Lilly and Company during the first quarter worth about $40,000. Finally, TD Capital Management LLC increased its position in Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after buying an additional 31 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently issued reports on LLY. Leerink Partners reaffirmed a “market perform” rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Hsbc Global Res raised Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Saturday, September 27th. Berenberg Bank reiterated a “hold” rating and issued a $830.00 price objective (down from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. Finally, HSBC raised their target price on shares of Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $938.94.

Insider Activity at Eli Lilly and Company

In related news, CEO David A. Ricks acquired 1,632 shares of the company’s stock in a transaction on Tuesday, August 12th. The stock was purchased at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the acquisition, the chief executive officer directly owned 546,601 shares of the company’s stock, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gabrielle Sulzberger bought 117 shares of the business’s stock in a transaction dated Tuesday, August 12th. The shares were bought at an average price of $641.18 per share, with a total value of $75,018.06. Following the completion of the transaction, the director owned 2,703 shares in the company, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders purchased 4,514 shares of company stock valued at $2,894,841. 0.14% of the stock is currently owned by company insiders.

Eli Lilly and Company Stock Up 0.7%

LLY opened at $845.40 on Tuesday. The stock has a fifty day moving average of $735.35 and a 200-day moving average of $765.48. The company has a market capitalization of $800.14 billion, a P/E ratio of 55.25, a P/E/G ratio of 1.17 and a beta of 0.47. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $937.00. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the firm earned $3.92 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.